Document is current
Any future updates will be listed below
-
Authors
Cong, Rong
Wu, Fan
Zhai, Yirui
Ye, Feng
Wang, Shuang
Chen, Zhaowei
Feng, Bing
Wang, Leyao
Zhu, Yongjian
Wang, Sicong
Zhao, Xinming
Chen, Bo
Ma, Xiaohong https://orcid.org/0000-0002-9048-8374
-
Funding
Funding for this research was provided by:
Beijing Hope Run Special Fund of Cancer Foundation of China (LC2022A14)
CAMS Innovation Fund for Medical Sciences (2021-I2M-1-066 and 2022-I2M-C&T-B-062)
- License Information
-
More Information
Article History
Received: 9 February 2025
Accepted: 7 September 2025
First Online: 16 October 2025
Declarations
:
: This study was conducted under a prospective phase 2 nonrandomized controlled trial (ClinicalTrials.gov identifier: NCT02580929) approved by the ethical committee of the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences (Number: NCC2014 YP-22).
: Written informed consent was obtained from all of the patients before participating in the clinical trial.
: S.C.W. is affiliated with GE Healthcare. The remaining authors declare that they have no competing interests.
